Analysis of p53 inactivation in a human T-cell leukemia virus type 1 Tax transgenic mouse model.
Analysis of p53 inactivation in a human T-cell leukemia virus type 1 Tax transgenic mouse model.
复制标题
人类 T 细胞白血病病毒 1 型 Tax 转基因小鼠模型中 p53 失活的分析。
DOI:
10.1128/jvi.75.5.2185-2193.2001
复制
发表时间:
2001
影响因子:
5.4
通讯作者:
Ratner,L
中科院分区:
文献类型:
--
作者:
Portis,T;Grossman,WJ;Harding,JC;Hess,JL;Ratner,L
MATERIALS AND METHODSMice. Granzyme B-Tax transgenic mice (Tax) were generated as previously described (14). Mice containing a homozygous deletion in p53 (p53/) were purchased from Jackson Laboratories (18). Tax mice were mated with p53/mice, and the resulting p53/Tax progeny were mated for production of F2 progeny. F2 mice were monitored weekly for rates of tumor formation, morbidity, and mortality. Pathological characteristics of tumors were compared among p53/Tax, p53/Tax, p53/Tax, p53/, p53/, and p53/transgenic littermates. All genotyping was performed as described previously (14; Jackson Laboratories protocol). Tissues were fixed in 10% neutral-buffered formalin, embedded in paraffin for sectioning, and stained with hematoxylin and eosin as described previously (14). All mice were bred and maintained under pathogen-free conditions in accordance with Washington University animal care guidelines. Kaplan-Meier analysis and statistical calculations were carried out using the SPSS statistical analysis program (SPSS, Inc.). Tissues and cell lines. Fresh tumors and tissues removed from mice were released into medium supplemented with 10% fetal bovine serum, 1% L-glutamine, 1% sodium pyruvate, and 1% penicillin-streptomycin (RPMI medium; Life Technologies). Erythrocytes in splenocyte preparations were lysed with 155 mM ammonium chloride and washed prior to culture. The tumor-derived F8 and SC large granular lymphocytic (LGL) cell lines have been described elsewhere and were maintained in RPMI medium (14, 15). Abelson murine leukemia virus (MLV)-transformed pre-B-cell lines containing wild-type (204-3-1) and mutant (143-2M) p53 were provided by Naomi Rosenberg (Tufts University, Boston, Mass.)(43) and maintained in RPMI medium. The human H1299 non-small-cell lung carcinoma cell line was provided by Rainer Brachmann (Washington University, St. Louis, Mo.) and maintained in Dulbecco modified Eagle medium (DMEM)(Life Technologies) supplemented with 10% fetal bovine serum, 1%